Urigen's pipeline includes URG101, targeting the treatment of painful bladder syndrome (PBS), symptoms of pelvic bladder syndrome secondary to pelvic irradiation and dyspareunia; URG301, targeting acute urgency in patients diagnosed with overactive bladder, acute urethral discomfort and urethritis; and URG302, a follow-on program targeting acute urgency in patients diagnosed with overactive bladder.
View the product pipeline

Apr 27 2009 - Urigen Pharmaceuticals Provides Corporate Update on Partnering Activities and Pursuit of Strategic Alternatives

Apr 16 2009 - Urigen Pharmaceuticals Announces Medical Television Show To Highlight Diagnosis and Need for Treatment of Painful Bladder Syndrome/Interstitial Cystitis

Mar 27 2009 - Harvard Medical School Study Validates Opportunity for Urigen Pharmaceuticals' Platform Technology To Develop Treatment for Painful Bladder Syndrome

Mar 12 2009 - Urigen Pharmaceuticals, Inc. Appoints Jeffrey G. Proctor, M.D. to Scientific Advisory Board

Feb 4 2009 - Urigen Announces Recent Insider Purchases Total Over 500,000 Shares

Jan 12 2009 - Urigen Pharmaceuticals Completes $257,000 Financing

Aug 19 2008 - Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis

Apr 25 2008 - Urigen Announces US Patent Office Notice of Allowance of Claims for URG101

Mar 12 2008 - Urigen Announces Positive Phase II Clinical Trial Results with URG101
Archives

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications. Urigen has two primary programs in development that are either in or positioned to enter Phase II clinical trials.